Chapter 37: Thyroid & Parathyroid Agents

Thyroid & Parathyroid Agents nursing pharmacology chapter explores the crucial therapeutic agents used to manage endocrine dysfunction of the thyroid and parathyroid glands, focusing primarily on restoring metabolic balance and maintaining calcium homeostasis in the body. The thyroid gland utilizes dietary iodine to synthesize essential thyroid hormones, specifically thyroxine (T4) and triiodothyronine (T3), which regulate the overall rate of metabolism, influencing heat production, oxygen consumption, and cardiac output. The precise production and release of T3 and T4 are tightly controlled by the intricate hypothalamic–pituitary–thyroid axis via thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH) through a sensitive negative feedback mechanism. Thyroid dysfunction manifests either as hypothyroidism (insufficient hormone, leading to severe lack called myxedema in adults or cretinism in infants) or hyperthyroidism (excessive hormone, often caused by Graves disease or resulting in a goiter). Hypothyroidism is typically managed with lifelong thyroid hormone replacement therapy, where the synthetic T4 salt, levothyroxine, is the most frequently prescribed agent, although the sources stress that these hormones are not indicated or safe for treating obesity. Hyperthyroidism treatments aim to block hormone production using thioamides such as methimazole (the preferred antithyroid drug, though propylthiouracil or PTU may be used in certain situations like pregnancy) or to destroy glandular tissue using iodine preparations, including radioactive iodine (sodium iodide I131). Separately, the parathyroid glands produce parathormone (PTH) which, along with calcitonin (from the thyroid), regulates serum calcium levels, critical for nerve function, muscle contraction, and blood clotting. Disorders related to calcium imbalance include hypocalcemia (treated with Vitamin D compounds like calcitriol and specific PTH forms like teriparatide) and hypercalcemia (associated with Paget disease, postmenopausal osteoporosis, or malignancy). Antihypercalcemic agents work to lower serum calcium; the bisphosphonates (e.g., alendronate) slow bone resorption, but must be administered carefully (taken with a full glass of water, remaining upright for 30 minutes) to prevent esophageal erosion. Another lowering agent is calcitonin salmon, which inhibits bone resorption. Nursing considerations emphasize the need for regular monitoring of thyroid and calcium levels, adherence to specific administration rules, and lifelong education for patients on replacement therapy.